# Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

> **NCT06052839** · PHASE2 · RECRUITING · sponsor: **Dan Zandberg** · enrollment: 15 (estimated)

## Conditions studied

- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06052839
- **Lead sponsor:** Dan Zandberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-03
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06052839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06052839, "Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT06052839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*